How did the profit decline compare to the revenue decline?

Net profit fell **30%** while total income dropped **11%**. The disparity suggests margin erosion was a bigger driver of the earnings hit than the top-line contraction alone.

What was the exceptional charge related to?

The company recorded a **₹3.27 crore** exceptional expense from implementing new national labor codes. This is a one-time cost acknowledged in the filing.

What dividend did the board recommend?

The board recommended a final dividend of **₹7.55** per equity share. The record date is July 24, 2026.

Did the filing include any leadership changes?

Yes, the board appointed Mrs. Ekta Gupta as an independent director. No other executive or board changes were noted.

Earnings · Pharmaceuticals · Mid cap

Concord Biotech profit falls 30% as revenue contracts 11%

FY26 net profit dropped to ₹259.23 crore from ₹371.64 crore, with total income shrinking to ₹1,107.25 crore.

— 2 earlier stories on Concord Biotech Ltd. →

CONCORDBIO By Tipsheet Editorial 29 May 2026 · 8:17 PM IST Verify on BSE · NSE

Mkt cap₹10,997 cr

P/E35.19×

ROE20.50%

Debt / eq.0.00

Div yld1.02%

30% Year-on-year decline in FY26 consolidated net profit

What's new

Net profit fell 30% to ₹259.23 crore in FY26, down from ₹371.64 crore in FY25.
Total income contracted 11% to ₹1,107.25 crore over the same period.
Board recommended a final dividend of ₹7.55 per share and appointed independent director Ekta Gupta.

Why this matters

This is a full-year earnings miss, not a quarterly blip. A 30% profit drop on an 11% revenue decline means margins compressed harder than the top line, pointing to cost pressures or a less favorable product mix. The ₹7.55 dividend offers little offset to the erosion in profitability.

What we're watching

Management's explanation for the margin compression beyond the headline revenue drop.
Whether the ₹3.27 crore labor-code charge is a one-off or the start of a new cost line.
Any forward guidance on revenue recovery or cost restructuring plans.

The full read

Concord Biotech's audited FY26 numbers are a clear step down. Net profit fell 30% to ₹259.23 crore. Total income shrank 11% to ₹1,107.25 crore. The profit hit was sharper than the revenue drop. Margins compressed. The board is paying out a final dividend of ₹7.55 per share, a modest gesture against a full year of deteriorating earnings. A one-time ₹3.27 crore charge for new labor codes is noted. The filing is a definitive, backward-looking record. It gives no guidance on whether this trough marks a cyclical low or a new baseline for the biotech's profitability.

Questions answered

How did the profit decline compare to the revenue decline?: Net profit fell 30% while total income dropped 11%. The disparity suggests margin erosion was a bigger driver of the earnings hit than the top-line contraction alone.
What was the exceptional charge related to?: The company recorded a ₹3.27 crore exceptional expense from implementing new national labor codes. This is a one-time cost acknowledged in the filing.
What dividend did the board recommend?: The board recommended a final dividend of ₹7.55 per equity share. The record date is July 24, 2026.
Did the filing include any leadership changes?: Yes, the board appointed Mrs. Ekta Gupta as an independent director. No other executive or board changes were noted.

Mentioned: Concord Biotech · ₹259.23 crore net profit · ₹7.55 dividend

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on CONCORDBIO →

29 May 2026 · 8:17 PM IST Concord Biotech profit falls 30% as revenue contracts 11%
1d ago Concord Biotech profit falls 30% on a 12% revenue slide
1d ago Concord Biotech profit drops 30% as revenue contracts for the year